Banzai Charging

December 10, 2024

DENVER, Colo., Dec 10, 2024 (247marketnews.com)- Banzai International (NASDAQ: BNZI), Bristol Myers Squibb (NYSE: BMY), DXC Technology (NYSE: DXC), Siyata Mobile (NASDAQ: SYTA), uniQure (NASDAQ: QURE), and Chimerix (NASDAQ: CMRX)

Banzai International (NASDAQ: BNZI) stated that the Company agreed to acquire OpenReel, a digital video creation platform that enables companies to rapidly create high-quality, branded video content, for $19.6 million in shares of Banzai Class A Common Stock, and/or Pre-Funded Warrants exercisable for shares of Class A Common Stock. The move increases Banzai’s TTM revenue by 152%, to $10.9 million.

OpenReel’s enterprise customer roster includes Bristol Myers Squibb (NYSE: BMY), Ingram Micro (NYSE:INGM), DXC Technology (NYSE: DXC).

Joe Davy, Banzai’s Founder and CEO, commented, “Video is the future of enterprise marketing. OpenReel gives their customers a 10x advantage when creating branded video content. Their enterprise customers are a testament to the power of their solution.”

Lee Firestone, OpenReel’s CEO and co-founder, added, “We’re thrilled to join the Banzai family and take OpenReel to new heights. With Banzai’s support, we’re confident in accelerating the growth of our technology while becoming an integral part of their robust suite of marketing tools. We believe that OpenReel is the perfect complement to Demio, enabling seamless cross-collaboration and enhancing the value we deliver to marketers worldwide.”

Siyata Mobile (NASDAQ: SYTA) is positioned to squeeze after reporting increasing sales momentum of its Bluetooth Remote Speaker Mic (“RSM”), an ergonomic palm-held microphone that looks, feels and acts like a traditional wired palm microphone to deliver excellent Push-to-Talk (PTT) audio quality, following Siyata’s third quarter 2024 financial results report, in which Siyata set a new Company quarterly revenue record of $5.9 million, a 218%, or over $4 million, year-over-year increase and a 210%, or $4.0 million, quarter-over-quarter increase.

Users who prefer PTT conversations through their own Smartphone, rather than a PTT handset, Siyata’s rugged Bluetooth RSM can be used with a variety of Android and iOS Smartphones or Tablets, including Samsung and Apple (NASDAQ: AAPL).

Marc Seelenfreund, CEO of Siyata, commented, “We strive to provide a full suite of devices for the PTT market and are the only North American vendor that is solely focused on this $7 billion market*. This Bluetooth RSM with its rugged IP-65 rating adds another layer to our PTT portfolio so that we now have PTT handsets, PTT for vehicles, PTT for users of their own Smartphones whether iOS or Android, as well as a full line of accessories to provide the best PTT experience possible.  Novatek is a leader in Push-To-Talk communications in North America serving a breadth of industries. We are encouraged by the number of our Bluetooth RSM’s they have already sold and the expanding market opportunities for this accessory, which we will continue to pursue in 2025.”

Michelle Montgomery, Novatek’s VP of Sales & Marketing, added, “Siyata’s Bluetooth RSM is being well-received by many of our PTT customers including a large grocery store chain warehouse, a large school bus company, and others. The compact RSM strikes the right balance between performance and price to provide our PTT customers with great audio performance.”

Seelenfreund, previously stated, “We are also extremely excited with our sales outlook going forward as we are now seeing tangible, rapid adoption of our unique PTT product portfolio across our various sales channels.  We believe that we have a very exciting 5G product portfolio planned to launch in 2025 which will position us as the leading PTT handset provider on a global level.  We announced recently that T-Mobile is the first wireless carrier that will be launching part of the portfolio and will be releasing details of the innovative devices over the coming months.  We are optimistic that more wireless carriers will follow suit.

“Our strategy to place Siyata’s PTT devices into the hands of top carriers is driving the top-line growth our shareholders have been waiting for. This partnership with T-Mobile, coupled with the launch of the SD7 Ultra 5G models, underscores our commitment to delivering innovative solutions for mission-critical needs. Our devices offer unmatched sound quality and rugged reliability, making them essential tools for enterprise customers.”

uniQure (NASDAQ: QURE) reported that the company agrees with the U.S. Food and Drug Administration (FDA) on key elements of an AMT-130 Accelerated Approval pathway.

Walid Abi-Saab, M.D., uniQure’s chief medical officer, stated, “We are very pleased to reach agreement with the FDA on core components of an Accelerated Approval pathway for AMT-130. Our alignment reflects the strength of our data and collaborative discussions with the staff and senior management at FDA’s Center for Biologics Evaluation and Research (CBER). This is an important milestone for the Huntington’s disease community as it puts us on the most rapid and efficient pathway to deliver a potentially life-changing therapy to people living with this devastating neurodegenerative disorder. We have initiated BLA readiness activities and look forward to further engaging with the FDA in the first half of 2025 to discuss our statistical analysis plan and the technical CMC requirements.”

Chimerix (NASDAQ: CMRX) stated that the Company will submit a New Drug Application (NDA) requesting accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States this month, following extensive dialogue with the U.S. Food and Drug Administration (FDA).

If the FDA grants Priority Review, the resulting six-month FDA review period is expected to result in a potential initial Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2025.

Mike Andriole, CEO of Chimerix, commented, “We expect that, if approved, dordaviprone will fundamentally change the treatment landscape for patients suffering from this lethal form of brain cancer who have extremely limited treatment options. We have worked collaboratively with the U.S. FDA, disease experts and patient advocates throughout the year to potentially accelerate access to dordaviprone for this patient community.

“In anticipation of a potential approval, we have bolstered our commercial leadership team and will be ready for a U.S. launch as early as the third quarter of 2025, pending application acceptance and Priority Review, if granted.”

Allen Melemed M.D., Chimerix’s Chief Medical Officer, added, “As a pediatric oncologist, this program is particularly meaningful given the impact a potential approval would have on children and young adults devastated by this disease. We are confident that the data generated to date could support an accelerated approval for this urgent unmet medical need.

“H3 K27M mutant gliomas are extremely aggressive and affect over 2,000 patients annually in the United States. If successful, dordaviprone would be the first FDA-approved therapy for this lethal disease, as well as one of the first molecularly defined approvals for any high-grade glioma.”

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

24/7 Market News disclosure

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BNZI, BMY, DXC, SYTA, QURE, CMRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.